Floatz logo

Theprubicin

Oxaliplatin

Zhejiang Cancer HospitalSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

13 Active assets in the Oxaliplatin cohort.

Asset / SponsorPhaseRating
Eloxatin
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2B
Calcium folinate pentahydrate
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2B
FLUOROURACILUM
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2B
Donafenib
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2B
Tislelizumab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2CCC

View all 17 →

Same molecule, other indications

Theprubicin is also rated in:

hepatocellular carcinomaDormant
BB
Indicative ·
71 / 100
View asset →
Transarterial ChemoembolizationDormant
BB
Indicative ·
66 / 100
View asset →
Colon Cancer Liver MetastasisDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →